BioWorld

May 26, 2005

View Archived Issues

Earlier-Stage Deals Demand 'Creative' Structuring Efforts

Read More

House Passes Stem Cell Bill; Bush Veto Looms On Horizon

Read More

Cylene Brings In $26M To Further Lead Cancer Drug

Read More

InterMune Finds Buyer For Amphotec In Three Rivers

Read More

Other News To Note

Read More

Encysive Submits Thelin NDA In PAH, Seeks Accelerated Review

Encysive Pharmaceuticals Inc. set its lead drug candidate, Thelin (sitaxsentan), on the pathway toward approval for pulmonary arterial hypertension by filing a new drug application with the FDA. (BioWorld Today) Read More